M.S. A.
- Country
- Spain
- Department
- Hematology
Research Overview
- HOVON 150 AML: A phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therapy in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2, with an IDH1 or IDH2 mutation, respectively, eligible for intensive chemotherapy.
- HOVON 156 AML: A phase 3, multicenter, open-label, randomized, study of gilteritinib versus midostaurin in combination with induction and consolidation therapy followed by one-year maintenance in patients with newly diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic syndromes with excess blasts-2 (MDS-EB2) with FLT3 mutations eligible for intensive chemotherapy.
Data & Insights
Has run more than one trial at 104 of 168 partner sites.
Specializations
Hematologic Malignancies
Specializes in the clinical evaluation of Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Lymphocytic Leukemia, various B‑cell and T‑cell lymphomas, and Multiple Myeloma.
- AML with IDH mutations
- High‑risk MDS
- Follicular Lymphoma
- Diffuse Large B‑Cell Lymphoma
- Plasma cell myeloma
Therapeutic strategies include novel agents, combination regimens, and risk‑adapted treatment pathways.
Stem Cell Transplantation & Graft‑Versus‑Host Disease
Leads investigations into allogeneic hematopoietic stem cell transplantation and the prevention and treatment of both acute and chronic Graft‑Versus‑Host Disease.
- Transplant conditioning protocols
- GVHD prophylaxis using JAK inhibition
- Management of steroid‑refractory GVHD
- Post‑transplant relapse monitoring
- Donor selection and HLA matching
Focuses on improving transplant outcomes and quality of life for high‑risk hematologic patients.
Targeted Molecular Therapies in Myeloid Disorders
Explores precision medicine approaches for IDH1/2‑mutated and FLT3‑mutated myeloid neoplasms, integrating biomarker‑driven treatment algorithms.
- IDH inhibition in AML
- FLT3 inhibitor combinations
- TP53‑altered MDS interventions
- Epigenetic modulators for high‑risk disease
- MRD‑guided therapeutic escalation
Seeks to translate genetic insights into actionable clinical regimens.
Immunotherapy & Cellular Therapies
Participates in trials evaluating immune‑based interventions for B‑cell malignancies, including monoclonal antibodies, checkpoint inhibition, and CAR T‑cell platforms.
- Anti‑CD20 antibody combinations
- PD‑1/PD‑L1 blockade in lymphoma
- TranspoCART19 cellular therapy
- Bispecific T‑cell engagers
- Immune profiling for response prediction
Targets durable remission through harnessing the immune system.
Translational Oncology Across Solid Tumors
Extends clinical expertise to selected solid‑tumor indications, emphasizing molecularly defined subgroups such as HER2‑negative breast cancer, KRAS‑mutated lung cancer, and urothelial carcinoma.
- Biomarker‑guided breast cancer trials
- KRAS G12C targeted therapy
- HER2‑low breast cancer strategies
- Immune checkpoint approaches in urothelial carcinoma
- Combination regimens integrating targeted agents
Integrates hematologic insights to inform innovative treatment paradigms in solid cancers.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.